Goodwin IP Litigation members Keith Zullow and Sean Anderson wrote about the context surrounding the Federal Circuit’s Idenix decision and the Supreme Court’s decision not to hear the case. Read the by line in the Journal of Generic Medicine here.
Related Content
- In the PressJanuary 27, 2023
Cannabis Marketing Proposed Regulations in New York & Neighboring States (Bloomberg Law)
- AlertJanuary 6, 2023
FTC Proposes a Sweeping Rule That Would Ban Nearly All US Noncompete Agreements
- Goodwin InsightsSeptember 20, 2022
3 Reasons Beauty Cos. Should Consider Pursuing Patents
- AlertAugust 10, 2022
Recent Court Decisions Shed Light on Enforceability of Electronic Contracts in the U.S.
- AlertJuly 28, 2022
Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System
- AlertJuly 7, 2022
Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial
- AlertMay 6, 2022
U.S. Government Authorizes Transactions Related to Patent Protection in Russia
- AlertApril 27, 2022
Federal Circuit Clarifies Standard for Fair and Reasonable Exercise of Jurisdiction Based on Demand Letters
- Speaking EngagementsFebruary 1, 2023
ChIPs San Diego: Practicing IP Law and Balancing Life
- Press ReleaseJanuary 25, 2023
Storage Solutions To Be Acquired by Jungheinrich
- In the PressJanuary 20, 2023
Goodwin Adds IP Litigator In San Francisco (Law360)
- In the PressJanuary 20, 2023
Top 5 IP Considerations for Medtech Companies Transitioning To Data-enabled Product Solutions (MedCity News)
- Press ReleaseJanuary 19, 2023
Concert Pharmaceuticals To Be Acquired by Sun Pharmaceutical For $576 Million and Contingent Value Rights
- EventsJanuary 18, 2023
2023 Goodwin CLE Days Program
- Press ReleaseJanuary 18, 2023
Goodwin Expands California Litigation Team with Intellectual Property Partner Sharon Smith
- Press ReleaseJanuary 9, 2023
Merck and Kelun-Biotech Announce $9.5 Billion ADC Collaboration